Duality Biologics Secures $176M Investment to Accelerate Next-Generation ADC Therapeutics

Duality Biologics is thrilled to announce a landmark funding milestone, having raised US$176,000,000 in its latest investment round. This capital infusion marks a significant step forward for the clinical-stage innovator, which is focused on the discovery and development of next-generation Antibody-Drug Conjugate (ADC) therapeutics for patients battling cancer and autoimmune diseases. Over the years, Duality Biologics has established itself as a leader in ADC technology by building robust platforms that not only secure global intellectual property rights but also drive breakthrough advancements in disease biology and translational medicine. With this funding, the company plans to further accelerate the progression of its innovative pipeline—currently featuring four assets in global clinical studies and over ten additional product candidates in the preclinical stage. The funds will be strategically allocated to support both the expansion of ongoing international multi-center clinical trials and the enhancement of novel protein engineering techniques that underpin its “super ADC” molecules. This includes the development of diverse payload classes, bispecific ADCs, and dual payload ADCs, all of which aim to offer improved efficacy and safety over existing treatment modalities. By partnering with leading multinational pharmaceutical companies and harnessing its deep scientific expertise, Duality Biologics is committed to transforming the landscape of cancer and autoimmune disease therapies. This investment not only underscores the confidence of our investors in our research and innovative potential but also propels our mission to deliver groundbreaking treatments to patients in need. For more detailed information about Duality Biologics and our journey, please visit www.dualitybiologics.com.